The Gene therapy market was valued $2.26 Bn in 2020 and is expected grow at a CAGR of xx%.
Market Introduction and Overview
Gene therapy and novel therapeutics applying gene therapy-based techniques have experienced a
drastic advance in the past 10 years. Clinically functional gene therapies are established now for certain
diseases, and many other promising therapeutics have been developed, with such a trend being most
noticeable in the field of haematological diseases. Recent advances in gene therapy and gene therapy-
based approaches have been quite considerable, which include delivery vectors, gene engineering
technologies and application to chimeric antigen receptor (CAR) T cell therapy.
These advances have realized many of the unmet promises of gene therapy for genetic diseases.
Furthermore, the application of gene therapy technologies to non-hereditary diseases such as
malignancies has recently started to display positive outcomes, such as with CAR-T cell therapy and the
oncolytic virus. The ongoing advances in gene therapy is boosting the market growth.
Gene therapy has been an active area of research for at least the past two decades. As of January 28,
2018, ten gene therapy products have been approved for marketing in at least one country in the world.
Recent predictions for the near future range from 12 to 14 new gene therapies submitted for approval in
the next couple of years, to around 40 new therapies approved by the end of 2022.
The gene therapy field is growing at an unprecedented pace. Healthcare giants are focusing on
establishments of own products and platforms which will propel their presence in the market.
Strengthening internal capabilities, external strategic collaborations and technology acquisitions by key
market players are expanding the market.
On December 9 2020, Bayer recently announced the launch of a cell and gene therapy platform (C>)
within its pharmaceutical division. The platform will further consolidate company’s emerging leadership in
the cell an